SCHEMBL7014369

SCHEMBL7014369

O=C(O)CCSc1cc2cc(Cl)ccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.51
F3 P13726 1/20 0.51
SIRT1 Q96EB6 1/20 0.47
FFAR1 O14842 5/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
PPARG P37231 2/20 0.44
DAO P14920 1/20 0.44
PYGL P06737 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NHERF1 O14745 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7014957 0.89 ALOX15 (0.47) PRKAG1PRKAA2PRKAB1RAB9ASMN1; SMN2
SCHEMBL949393 0.81 SMN1; SMN2 (0.44) F7F3SIRT1RAB9AMEN1
SCHEMBL9871123 0.81 AR (0.58) PRKAG1PRKAA2PRKAB1RAB9ANPC1
SCHEMBL7016534 0.74 TP53 (0.46) FFAR1PRKAG1PRKAA2PRKAB1RAB9A
SCHEMBL30222912 0.72 SIRT1 (0.58) F7F3SIRT1FFAR1RAB9A
SCHEMBL5097277 0.71 SIRT1 (0.74) F7F3SIRT1FFAR1RAB9A
SCHEMBL10593440 0.70 SIRT1 (0.56) F7F3SIRT1FFAR1RAB9A
SCHEMBL6609114 0.69 SMN1; SMN2 (0.53) FFAR1PRKAG1PRKAA2PRKAB1RAB9A
SCHEMBL5891883 0.69 PYGL (0.67) F7F3PYGLNHERF1HRH4
SCHEMBL10850338 0.69 SIRT1 (0.57) F7F3SIRT1FFAR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187023-A1 Sulfone derivatives, process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1302462-A1 SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187023-A1 Sulfone derivatives, process for their production and use thereof SULT1E1, RRS1, SHH F7 579/4885F3 505/4885SIRT1 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.